BioVie to Unveil Bezisterim Data in Parkinson’s and Long COVID at ANA2026
Event summary
- BioVie will present Phase 2 trial results for bezisterim in Long COVID (ADDRESS-LC) and Parkinson’s disease (SUNRISE-PD) at ANA2026.
- Poster sessions scheduled for October 18–19, 2026, in San Diego.
- Bezisterim showed improvements in inflammation biomarkers and clinical symptoms in both trials.
- ADDRESS-LC enrolled ~200 patients; SUNRISE-PD enrolled 57 early-stage Parkinson’s patients.
The big picture
BioVie’s dual focus on Long COVID and Parkinson’s reflects the growing intersection of neuroinflammatory therapies and post-viral syndromes. The company’s hybrid trial design for SUNRISE-PD suggests a strategic pivot toward proof-of-concept validation, while ADDRESS-LC’s subgroup signals hint at a potential niche in Long COVID’s heterogeneous patient population. Success here could position bezisterim as a multi-indication asset, though regulatory hurdles remain.
What we're watching
- Clinical Validation
- Whether bezisterim’s Phase 2 biomarker and symptom improvements translate into statistically significant outcomes in larger trials.
- Regulatory Pathway
- The FDA’s stance on surrogate endpoints for Long COVID, given the exploratory nature of ADDRESS-LC’s subgroup analyses.
- Competitive Positioning
- How BioVie differentiates bezisterim in the crowded neuroinflammation space, particularly for Parkinson’s and Alzheimer’s.